Literature DB >> 28398627

Aryl hydrocarbon receptor promotes hepatocellular carcinoma tumorigenesis by targeting intestine-specific homeobox expression.

Shih-Hsien Hsu1,2,3, Li-Ting Wang1, Chee-Yin Chai4, Chi-Cheng Wu5, Edward Hsi6, Shyh-Shin Chiou7,8, Shen-Nien Wang9,10.   

Abstract

The aryl hydrocarbon receptor (AHR), a major chemical sensor, is thought to play a role in various biological contexts, including cell cycle regulation and tumorigenesis. However, its regulatory mechanisms remain unclear. We propose herein a novel mechanism through which AHR promotes tumorigenesis by targeting expression of the oncogene intestine-specific homeobox (ISX) in hepatocellular carcinoma (HCC). Compared to paired tumor-adjacent tissues and non-HCC tumors, HCCs exhibited an increased and hierarchical pattern of AHR expression. Patients exhibiting high AHR expression had a significantly shorter survival duration, compared to those with low and medium expression. Functionally, AHR was found to target the newly discovered proto-oncogene, ISX, resulting in the increased expression of this gene and its downstream targets, CCND1 and E2F1. Ablation of AHR or ISX in hepatoma cells suppressed cell growth, whereas overexpression promoted cell proliferation and led to enhanced tumorigenic activity in vitro and in vivo. These results provide evidence to support a critical role for the AHR/ISX axis in HCC tumorigenesis and suggest its potential utility as a new therapeutic and prognostic target for HCC.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  aryl hydrocarbon receptor (AHR); hepatocellular carcinoma (HCC); intestine-specific homeobox (ISX)

Mesh:

Substances:

Year:  2017        PMID: 28398627     DOI: 10.1002/mc.22658

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Retracted Article: Synthesis of xanthone derivatives and anti-hepatocellular carcinoma potency evaluation: induced apoptosis.

Authors:  Jie Liu; Hui Bao; Huailing Wang; Qiang Luo; Jianhong Zuo; Zhigang Liu; Shuqi Qiu; Xizhuo Sun; Xiaoyu Liu
Journal:  RSC Adv       Date:  2019-12-09       Impact factor: 4.036

Review 2.  Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.

Authors:  Kwei-Yan Liu; Li-Ting Wang; Shih-Hsien Hsu
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

3.  The AHR pathway represses TGFβ-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma.

Authors:  Nemanja Sarić; Matthew Selby; Vijay Ramaswamy; Marcel Kool; Brigitta Stockinger; Christer Hogstrand; Daniel Williamson; Silvia Marino; Michael D Taylor; Steven C Clifford; M Albert Basson
Journal:  Sci Rep       Date:  2020-01-10       Impact factor: 4.379

4.  TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway.

Authors:  Lei Li; Tao Wang; Shanbao Li; Zhengqian Chen; Junyi Wu; Wanyue Cao; Qi Wo; Xuebin Qin; Junming Xu
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

5.  AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma.

Authors:  Qing Zhu; Yarui Ma; Junbo Liang; Zhewen Wei; Mo Li; Ying Zhang; Mei Liu; Huan He; Chunfeng Qu; Jianqiang Cai; Xiaobing Wang; Yixin Zeng; Yuchen Jiao
Journal:  Signal Transduct Target Ther       Date:  2021-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.